Relief Therapeutics Holding AG (RLFTF)

[Uncle Gee Gee]

Assuming we get the Half-Year Report tomorrow, here are some of the things I’m looking for. Did I miss anything?

1) What does the Share Capital section of the report show? What are the current total and outstanding shares?

2) Is Dr. Ram, Peter, Javitt, Neuro or anyone else now considered a major shareholder or received any shares or compensation?

3) If they generated any revenue, what was it from? Not expecting any/much, but it would be interesting to see if they charged for the trial drugs, and if so, how much?

4) How much of the remaining GEM Share Subscription Facility (CHF $43.8 million) did they use and how much (if any) remains available for drawdown?

5) What other sources of cash did they get and how much? Princeton Angels?

6) How much money did they actually burn through for trials and other business activities?

7) How much cash do they have remaining on hand?

8) Are there any updated comments about how much money they need to finalize trials, infrastructure, ramp up, compensation, etc?

9) Did they redo the Aviptadil impairment test in light of the new Covid-19 application? If so, what is the new valuation, and what details do they provide in the accompanying Sensitivity Analysis?

10) Are there any partnership comments regarding NeuroRX, manufacturers, or distributors?

11) Where there any other staffing changes other than hiring the Chief Medical Officer for European expansion?

12) Do they make any comments about hiring a CEO or other key positions?

13) Which Execs and Board members received compensation (who’s the core group remaining)?

14) And of course… any updates on trial results, DMC, etc?


Anything else you guys are looking for?